Iradimed Corp (NASDAQ:IRMD) VP Sells $62,190.00 in Stock

Share on StockTwits

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 3,000 shares of Iradimed stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $20.73, for a total value of $62,190.00. Following the completion of the transaction, the vice president now owns 2,368 shares in the company, valued at $49,088.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Brent Johnson also recently made the following trade(s):

  • On Friday, June 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.00, for a total value of $20,000.00.
  • On Monday, June 10th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.06, for a total value of $20,060.00.
  • On Wednesday, June 12th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $20.57, for a total value of $61,710.00.
  • On Friday, June 7th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.00, for a total value of $20,000.00.
  • On Thursday, May 23rd, Brent Johnson sold 4,000 shares of Iradimed stock. The shares were sold at an average price of $21.78, for a total value of $87,120.00.
  • On Monday, May 20th, Brent Johnson sold 2,000 shares of Iradimed stock. The shares were sold at an average price of $22.53, for a total value of $45,060.00.
  • On Friday, May 17th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $21.83, for a total value of $65,490.00.

Shares of IRMD stock traded up $0.62 during midday trading on Wednesday, hitting $21.56. The company had a trading volume of 74,100 shares, compared to its average volume of 62,389. Iradimed Corp has a 52-week low of $18.60 and a 52-week high of $38.78. The company has a market capitalization of $226.27 million, a P/E ratio of 50.14 and a beta of 1.78. The company has a current ratio of 9.48, a quick ratio of 8.63 and a debt-to-equity ratio of 0.06.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.11. Iradimed had a return on equity of 13.98% and a net margin of 23.00%. The firm had revenue of $8.44 million for the quarter, compared to the consensus estimate of $8.38 million. As a group, equities analysts predict that Iradimed Corp will post 0.64 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Iradimed by 19.7% in the third quarter. Vanguard Group Inc. now owns 250,298 shares of the medical equipment provider’s stock valued at $9,298,000 after buying an additional 41,184 shares in the last quarter. Ranger Investment Management L.P. boosted its stake in shares of Iradimed by 13.3% in the fourth quarter. Ranger Investment Management L.P. now owns 190,226 shares of the medical equipment provider’s stock valued at $4,653,000 after buying an additional 22,341 shares in the last quarter. Cadence Capital Management LLC boosted its stake in shares of Iradimed by 64.7% in the first quarter. Cadence Capital Management LLC now owns 129,955 shares of the medical equipment provider’s stock valued at $3,650,000 after buying an additional 51,050 shares in the last quarter. RK Capital Management LLC purchased a new stake in shares of Iradimed in the first quarter valued at approximately $3,648,000. Finally, Spark Investment Management LLC boosted its stake in shares of Iradimed by 86.4% in the first quarter. Spark Investment Management LLC now owns 56,100 shares of the medical equipment provider’s stock valued at $1,575,000 after buying an additional 26,000 shares in the last quarter. Hedge funds and other institutional investors own 23.53% of the company’s stock.

Several brokerages have weighed in on IRMD. BidaskClub downgraded Iradimed from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Zacks Investment Research upgraded Iradimed from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Tuesday, May 7th. Finally, ValuEngine downgraded Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Iradimed currently has a consensus rating of “Buy” and an average price target of $31.50.

ILLEGAL ACTIVITY NOTICE: “Iradimed Corp (NASDAQ:IRMD) VP Sells $62,190.00 in Stock” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4380021/iradimed-corp-nasdaqirmd-vp-sells-62190-00-in-stock.html.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Story: What is a stock portfolio tracker?

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report